After years of delays Pfizer and Eli Lilly’s tanezumab non-opioid pain drug is edging closer to approval, after it met targets in an osteoarthritis trial. Tanezumab is a nerve growth factor (NGF ...
This allowed Regeneron and Teva to continue with trials on fasinumab, and Pfizer and Eli ... treat their chronic pain, other than with non-steroidal anti-inflammatory drugs or opioids.” ...
Why don’t doctors necessarily hand out free Viagra samples anymore? Viagra is now available as a generic, making it more ...
Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...
Amid rising concerns about benzodiazepines, some patients who try to quit are suffering extreme anxiety, memory loss and ...
Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...
MedPage Today on MSN3d
Topical JAK Inhibitor Active in Itchy Prurigo NodularisORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...
President Donald Trump’s nominee for FDA Commissioner, Martin A. Makary, MD, sought to assure senators that if confirmed, he would support efforts to expedite reviews of new drugs indicted for rare ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback